Intellipharmaceutics International Inc.

TSXV:IPCI.H Stock Report

Market Cap: CA$2.6m

Intellipharmaceutics International Past Earnings Performance

Past criteria checks 0/6

Intellipharmaceutics International has been growing earnings at an average annual rate of 35.8%, while the Pharmaceuticals industry saw earnings growing at 59.3% annually. Revenues have been declining at an average rate of 43.4% per year.

Key information

35.8%

Earnings growth rate

74.2%

EPS growth rate

Pharmaceuticals Industry Growth23.1%
Revenue growth rate-43.4%
Return on equityn/a
Net Margin-350.7%
Last Earnings Update31 Aug 2023

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Intellipharmaceutics International makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

TSXV:IPCI.H Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Aug 231-312
31 May 231-202
28 Feb 230-202
30 Nov 220-312
31 Aug 220-413
31 May 220-513
28 Feb 220-513
30 Nov 210-513
31 Aug 210-513
31 May 211-323
28 Feb 211-323
30 Nov 201-324
31 Aug 201-324
31 May 203-634
29 Feb 204-735
30 Nov 193-847
31 Aug 194-1158
31 May 192-13410
28 Feb 192-14411
30 Nov 182-14311
31 Aug 182-12410
31 May 183-1149
28 Feb 185-10310
30 Nov 176-939
31 Aug 175-10310
31 May 174-10410
28 Feb 173-10410
30 Nov 162-1048
31 Aug 163-935
31 May 163-933
29 Feb 164-930
30 Nov 154-747
31 Aug 155-640
31 May 155-540
28 Feb 155-740
30 Nov 149-440
31 Aug 149-940
31 May 148-93-2
28 Feb 146-830
30 Nov 132-1130

Quality Earnings: IPCI.H is currently unprofitable.

Growing Profit Margin: IPCI.H is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: IPCI.H is unprofitable, but has reduced losses over the past 5 years at a rate of 35.8% per year.

Accelerating Growth: Unable to compare IPCI.H's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: IPCI.H is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (11.7%).


Return on Equity

High ROE: IPCI.H's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies